LOGIN  |  REGISTER

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 563.62
6.41 1.15
680,646
381.72M
US$ 215.150B
US$ 252.56
4.00 1.61
2.29M
740.69M
US$ 187.070B
US$ 105.47
-1.10 -1.03
2.82M
1.74B
US$ 183.520B
US$ 431.85
-0.70 -0.16
846,762
354.71M
US$ 153.180B
US$ 340.12
-1.23 -0.36
533,331
380.95M
US$ 129.570B
US$ 77.23
0.23 0.30
2.84M
1.47B
US$ 113.530B
US$ 80.95
0.78 0.97
2.71M
1.31B
US$ 106.040B
US$ 605.11
1.87 0.31
223,211
129.99M
US$ 78.660B
US$ 238.34
-0.06 -0.03
778,124
289.01M
US$ 68.880B
US$ 90.55
1.71 1.92
1.62M
602.60M
US$ 54.570B
US$ 115.58
-0.49 -0.42
1.17M
397.68M
US$ 45.960B
US$ 89.06
-0.38 -0.42
310,787
493.24M
US$ 43.930B
US$ 495.32
-0.64 -0.13
284,310
82.59M
US$ 40.910B
US$ 215.66
1.47 0.69
446,650
182.20M
US$ 39.290B
US$ 132.80
0.07 0.05
979,107
291.76M
US$ 38.750B
US$ 1.00
0.40 0.03
34,991
21.36M
US$ 31.120B
US$ 210.56
-2.71 -1.27
416,167
146.91M
US$ 30.930B
US$ 319.35
3.35 1.06
107,620
82.78M
US$ 26.440B
US$ 104.41
0.04 0.04
675,981
243.57M
US$ 25.430B
US$ 329.03
0.39 0.12
253,201
72.84M
US$ 23.970B
US$ 106.50
0.25 0.24
485,537
205.73M
US$ 21.910B
US$ 217.80
-1.51 -0.69
208,863
98.85M
US$ 21.530B
US$ 91.51
-0.22 -0.24
318,631
199.12M
US$ 18.220B
US$ 34.12
0.12 0.35
1.08M
509.58M
US$ 17.380B
US$ 205.57
-1.81 -0.87
179,655
84.29M
US$ 17.330B
US$ 107.88
-0.37 -0.34
1.01M
159.30M
US$ 17.190B
US$ 289.46
-0.54 -0.19
186,895
59.32M
US$ 17.170B
US$ 72.37
0.16 0.22
423,978
233.38M
US$ 16.890B
US$ 138.74
0.54 0.39
205,158
111.09M
US$ 15.410B
US$ 200.78
1.47 0.74
286,926
70.04M
US$ 14.060B
US$ 108.29
0.79 0.73
212,544
123.39M
US$ 13.360B
US$ 108.10
0.89 0.83
288,828
122.80M
US$ 13.270B
US$ 334.75
0.00 0.00
0
37.54M
US$ 12.570B
US$ 401.10
0.47 0.12
68,106
30.98M
US$ 12.430B
US$ 25.34
0.09 0.36
155,658
437.17M
US$ 11.080B
US$ 211.02
1.39 0.66
96,005
51.51M
US$ 10.870B
US$ 66.05
-0.49 -0.74
163,439
151.34M
US$ 10.000B
US$ 202.52
0.44 0.22
378,966
47.10M
US$ 9.540B
US$ 41.49
-0.40 -0.95
670,906
221.85M
US$ 9.200B
US$ 44.81
0.81 1.84
1.92M
184.53M
US$ 8.270B
US$ 67.18
0.17 0.25
407,822
112.63M
US$ 7.570B
US$ 132.40
2.01 1.54
186,236
53.09M
US$ 7.030B
US$ 177.52
2.07 1.18
84,085
38.76M
US$ 6.880B
US$ 121.55
1.55 1.29
516,256
55.88M
US$ 6.790B
US$ 284.20
-1.42 -0.50
114,670
23.45M
US$ 6.660B
US$ 112.29
0.63 0.56
227,152
50.37M
US$ 5.660B
US$ 79.37
-2.12 -2.60
293,776
69.31M
US$ 5.500B
US$ 15.09
0.00 0.00
163,848
351.48M
US$ 5.300B
US$ 167.99
0.28 0.17
144,716
29.71M
US$ 4.990B
US$ 81.79
0.28 0.34
109,796
58.11M
US$ 4.750B
US$ 139.91
-4.09 -2.84
464,646
32.94M
US$ 4.610B
US$ 85.67
0.17 0.20
172,404
50.95M
US$ 4.360B
US$ 58.40
1.12 1.96
373,370
73.88M
US$ 4.310B
US$ 115.82
0.07 0.06
79,612
33.50M
US$ 3.880B
US$ 29.72
0.16 0.54
482,901
122.37M
US$ 3.640B
US$ 16.48
-0.02 -0.12
976,154
216.61M
US$ 3.570B
US$ 67.63
0.31 0.46
139,614
51.02M
US$ 3.450B
US$ 68.03
2.75 4.21
229,783
49.92M
US$ 3.400B
US$ 11.90
0.32 2.76
259,410
283.07M
US$ 3.370B
US$ 105.50
0.13 0.12
146,679
31.10M
US$ 3.280B
US$ 25.54
0.02 0.08
336,573
124.34M
US$ 3.180B
US$ 59.80
-0.34 -0.57
316,584
51.42M
US$ 3.070B
US$ 56.93
0.20 0.35
151,573
53.92M
US$ 3.070B
US$ 56.21
0.58 1.04
289,371
54.15M
US$ 3.040B
US$ 49.82
1.08 2.22
339,759
58.23M
US$ 2.900B
US$ 116.49
-4.06 -3.37
137,928
24.37M
US$ 2.840B
US$ 43.00
0.43 1.01
340,781
64.59M
US$ 2.780B
US$ 46.43
0.27 0.58
265,629
58.14M
US$ 2.700B
US$ 34.99
0.15 0.43
259,769
66.97M
US$ 2.340B
US$ 28.69
-0.19 -0.66
345,014
78.80M
US$ 2.260B
US$ 56.00
0.04 0.07
201,340
39.25M
US$ 2.200B
US$ 24.15
0.35 1.47
327,376
90.51M
US$ 2.190B
US$ 67.44
0.27 0.40
116,740
30.80M
US$ 2.080B
US$ 19.23
0.05 0.26
168,870
107.61M
US$ 2.070B
US$ 40.78
0.66 1.65
163,781
49.13M
US$ 2.000B
US$ 81.61
1.02 1.27
78,282
22.45M
US$ 1.830B
US$ 13.17
0.16 1.23
307,246
127.71M
US$ 1.680B
US$ 15.55
-0.10 -0.64
408,931
99.13M
US$ 1.540B
US$ 11.52
0.23 2.04
374,574
133.20M
US$ 1.530B
US$ 18.01
0.20 1.12
476,531
84.62M
US$ 1.520B
US$ 10.16
-0.10 -0.98
378,084
139.88M
US$ 1.420B
US$ 17.01
0.08 0.47
315,360
76.50M
US$ 1.300B
US$ 42.05
-0.68 -1.59
346,270
27.51M
US$ 1.160B
US$ 7.18
0.09 1.27
10,950
156.42M
US$ 1.120B
US$ 22.63
-1.13 -4.76
379,800
48.38M
US$ 1.090B
US$ 26.91
-0.05 -0.19
2.49M
39.44M
US$ 1.060B
US$ 6.87
0.08 1.18
317,777
147.60M
US$ 1.010B
US$ 21.23
0.40 1.92
181,689
46.07M
US$ 978.070M
US$ 23.30
0.20 0.87
74,168
41.73M
US$ 972.310M
US$ 19.78
0.33 1.70
107,135
45.90M
US$ 907.860M
US$ 17.57
0.07 0.40
206,017
49.48M
US$ 869.240M
US$ 1.24
-0.005 -0.40
1.84M
696.99M
US$ 860.780M
US$ 451.62
1.62 0.36
9,979
1.76M
US$ 794.840M
US$ 14.12
0.15 1.07
278,601
52.19M
US$ 736.920M
US$ 5.55
0.09 1.65
222,294
131.27M
US$ 727.890M
US$ 1.90
-0.03 -1.30
1.14M
369.92M
US$ 701.000M
US$ 29.32
0.06 0.21
49,856
23.83M
US$ 698.700M
US$ 10.27
-0.38 -3.57
477,773
67.41M
US$ 692.300M
US$ 14.79
0.18 1.23
187,082
40.86M
US$ 604.320M
US$ 20.16
0.11 0.55
65,345
29.92M
US$ 603.190M
US$ 25.24
0.19 0.76
89,128
23.88M
US$ 602.730M
US$ 10.60
-0.51 -4.59
89,433
55.23M
US$ 585.440M
US$ 20.92
-0.16 -0.76
93,900
27.61M
US$ 577.460M
US$ 42.83
0.30 0.71
17,945
12.66M
US$ 542.230M
US$ 13.12
-0.29 -2.16
139,192
38.27M
US$ 502.100M
US$ 12.16
-0.05 -0.41
169,239
41.20M
US$ 500.830M
US$ 12.78
0.08 0.63
92,746
37.53M
US$ 479.450M
US$ 5.64
-0.11 -1.92
231,954
82.95M
US$ 467.420M
US$ 2.96
-0.08 -2.55
219,468
156.55M
US$ 463.800M
US$ 4.25
0.09 2.04
260,589
104.54M
US$ 443.770M
US$ 6.34
0.01 0.16
63,459
68.38M
US$ 433.190M
US$ 15.50
0.00 0.00
71,344
27.29M
US$ 423.000M
US$ 1.52
-0.06 -3.50
2.72M
272.36M
US$ 412.630M
US$ 6.93
0.20 2.97
850,912
57.79M
US$ 400.720M
US$ 5.91
0.05 0.85
211,290
62.01M
US$ 366.480M
US$ 5.51
-0.09 -1.61
163,805
63.83M
US$ 351.700M
US$ 4.57
0.03 0.55
554,381
73.96M
US$ 337.630M
US$ 8.87
0.28 3.26
271,687
36.73M
US$ 325.800M
US$ 6.36
0.00 0.00
47,946
49.76M
US$ 316.470M
US$ 6.86
0.05 0.73
125,783
43.70M
US$ 299.780M
US$ 8.72
-0.48 -5.22
5,455
34.36M
US$ 299.620M
US$ 9.06
-0.12 -1.31
60,465
31.78M
US$ 287.930M
US$ 11.53
0.39 3.50
118,517
23.76M
US$ 273.830M
US$ 6.56
0.04 0.61
71,381
38.82M
US$ 254.470M
US$ 35.22
-0.01 -0.03
199,666
7.07M
US$ 249.010M
US$ 11.24
0.12 1.08
167,221
21.60M
US$ 242.680M
US$ 28.02
-0.68 -2.37
18,957
8.63M
US$ 241.810M
US$ 67.13
0.10 0.15
6,004
3.53M
US$ 236.970M
US$ 5.89
-0.03 -0.51
273,978
40.05M
US$ 235.890M
US$ 5.92
0.10 1.72
109,892
38.82M
US$ 229.810M
US$ 8.03
-0.10 -1.23
79,578
27.79M
US$ 223.220M
US$ 6.90
-0.20 -2.82
47,203
31.69M
US$ 218.500M
US$ 8.80
-0.20 -2.22
22,970
24.43M
US$ 214.860M
US$ 8.31
0.00 0.00
82,607
25.80M
US$ 214.270M
US$ 0.39
0.0002 0.05
797,067
530.89M
US$ 207.150M
US$ 4.00
0.41 11.44
2.27M
51.72M
US$ 206.620M
US$ 5.26
-0.03 -0.57
8,012
37.10M
US$ 194.960M
US$ 8.08
0.22 2.80
88,840
23.58M
US$ 190.530M
US$ 6.62
0.02 0.30
36,222
28.77M
US$ 190.460M
US$ 1.88
0.05 2.73
243,476
99.24M
US$ 186.570M
US$ 1.60
-0.01 -0.62
9,982
114.69M
US$ 183.500M
US$ 5.30
0.00 0.00
92,194
34.49M
US$ 182.620M
US$ 0.93
-0.0043 -0.46
413,124
184.28M
US$ 172.120M
US$ 5.78
0.10 1.76
12,595
27.16M
US$ 156.990M
US$ 1.86
0.02 1.06
66,400
82.64M
US$ 153.670M
US$ 1.20
-0.11 -8.47
910,668
121.88M
US$ 146.130M
US$ 6.64
0.22 3.43
28,394
21.30M
US$ 141.430M
US$ 3.26
-0.04 -1.06
70,979
42.57M
US$ 138.570M
C$ 0.49
-0.01 -2.00
38,500
278.58M
C$ 136.500M
US$ 0.42
0.0014 0.34
1.21M
323.54M
US$ 135.600M
US$ 5.26
0.08 1.54
67,893
24.66M
US$ 129.710M
US$ 4.03
0.00 0.00
0
31.62M
US$ 127.270M
US$ 2.89
0.02 0.52
103,093
43.43M
US$ 125.300M
US$ 14.43
0.12 0.84
10,785
8.66M
US$ 124.960M
US$ 2.43
0.20 8.97
577,105
49.39M
US$ 120.020M
US$ 2.58
0.23 9.57
110,248
45.76M
US$ 117.830M
US$ 2.21
-0.39 -14.99
2.70M
47.95M
US$ 105.980M
US$ 6.17
-0.06 -0.96
12,247
16.66M
US$ 102.790M
US$ 0.25
0.02 6.33
1.79M
401.03M
US$ 101.060M
US$ 15.27
0.13 0.86
1,829
6.33M
US$ 96.630M
US$ 5.60
-0.16 -2.78
86,966
17.07M
US$ 95.590M
US$ 3.19
0.05 1.59
43,133
28.81M
US$ 91.900M
US$ 0.70
0.0018 0.26
52,473
130.27M
US$ 91.190M
US$ 0.33
0.0009 0.28
2.79M
272.44M
US$ 88.570M
US$ 5.23
0.04 0.77
23,284
16.39M
US$ 85.720M
US$ 2.30
0.16 7.48
20,423
31.67M
US$ 72.840M
US$ 2.65
-0.02 -0.75
5,551
27.29M
US$ 72.320M
US$ 3.60
0.12 3.45
79,264
20.04M
US$ 72.140M
US$ 6.78
-0.02 -0.29
1,046
10.26M
US$ 69.570M
US$ 1.25
0.00 0.00
60,766
54.98M
US$ 68.720M
US$ 2.52
0.003 0.12
4,090
24.96M
US$ 62.970M
US$ 18.40
-0.39 -2.08
3,521
3.42M
US$ 62.930M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 1.33
0.02 1.15
205,979
45.90M
US$ 60.820M
US$ 4.53
-0.15 -3.10
2.33M
13.33M
US$ 60.320M
US$ 2.25
-0.04 -1.56
16,664
26.33M
US$ 59.350M
US$ 1.78
0.00 0.00
0
31.88M
US$ 56.750M
US$ 0.68
0.02 2.88
20,723
82.82M
US$ 56.230M
US$ 1.85
0.06 3.59
35,788
30.00M
US$ 55.630M
US$ 1.08
-0.01 -0.92
84,765
51.23M
US$ 55.330M
US$ 2.57
0.00 0.00
0
20.76M
US$ 53.350M
US$ 0.69
0.02 2.24
24,610
77.23M
US$ 52.900M
US$ 0.77
-0.04 -4.95
967,629
69.11M
US$ 52.870M
US$ 1.57
-0.04 -2.48
7,402
30.99M
US$ 48.650M
US$ 1.38
0.05 3.76
3,851
34.64M
US$ 47.800M
US$ 4.15
-0.15 -3.56
5,594
11.40M
US$ 47.270M
US$ 2.40
0.00 0.00
1,162
19.60M
US$ 47.040M
US$ 1.81
0.09 5.23
128,719
25.97M
US$ 47.010M
US$ 1.50
0.05 3.45
64,094
31.28M
US$ 46.920M
US$ 0.82
0.0031 0.38
7,961
56.95M
US$ 46.700M
C$ 0.45
0.03 7.14
65,000
101.40M
C$ 45.630M
US$ 0.81
0.02 2.23
19,689
54.31M
US$ 43.900M
C$ 0.18
-0.005 -2.70
168,785
239.30M
C$ 43.070M
US$ 4.50
0.14 3.21
2,945
9.05M
US$ 40.720M
US$ 6.00
-0.11 -1.80
855
6.44M
US$ 38.630M
US$ 0.72
0.03 3.76
231,247
52.42M
US$ 37.720M
US$ 0.38
-0.73 -65.87
61,985
98.27M
US$ 37.350M
C$ 0.30
0.01 3.45
526
118.47M
C$ 35.540M
US$ 0.74
-0.0056 -0.75
21,945
47.94M
US$ 35.470M
C$ 0.32
-0.005 -1.54
34,415
109.52M
C$ 35.050M
US$ 2.15
0.18 9.14
30,193
16.25M
US$ 34.940M
US$ 1.17
0.08 7.12
32,667
29.92M
US$ 34.930M
C$ 0.22
0.02 10.00
391,900
156.82M
C$ 34.500M
US$ 1.12
-0.02 -1.42
42,881
29.94M
US$ 33.650M
US$ 1.93
-0.04 -1.79
5,088
17.37M
US$ 33.440M
US$ 1.54
-0.12 -7.23
268,395
20.07M
US$ 30.910M
US$ 1.27
0.02 1.60
6,396
23.61M
US$ 29.980M
US$ 0.78
0.00 0.00
7,751
37.55M
US$ 29.100M
US$ 1.61
0.02 1.25
58,745
17.48M
US$ 28.140M
US$ 1.20
-0.07 -5.54
473,707
22.22M
US$ 26.660M
C$ 0.39
-0.02 -3.75
124,500
65.06M
C$ 25.050M
US$ 0.34
0.02 4.80
17,181
74.09M
US$ 24.920M
US$ 1.34
-0.06 -4.29
66,059
17.38M
US$ 23.290M
US$ 2.45
-0.03 -1.01
3,437
9.47M
US$ 23.150M
US$ 0.83
-0.0028 -0.34
32,034
27.84M
US$ 23.030M
US$ 0.85
0.01 1.64
50,286
25.46M
US$ 21.610M
C$ 0.24
0.00 0.00
0
90.89M
C$ 21.360M
US$ 2.00
-0.02 -0.99
20,308
10.54M
US$ 21.080M
US$ 1.84
-0.02 -1.08
16,971
11.36M
US$ 20.900M
US$ 1.67
-0.01 -0.60
32,283
12.45M
US$ 20.790M
C$ 0.30
0.005 1.72
24,570
69.23M
C$ 20.420M
US$ 0.02
0.00 0.00
0
1.15B
US$ 20.240M
US$ 0.98
-0.01 -1.13
42,724
20.39M
US$ 19.960M
C$ 0.10
0.00 0.00
345,502
194.28M
C$ 19.430M
US$ 1.04
0.01 0.97
26,395
18.17M
US$ 18.900M
C$ 0.17
0.00 0.00
0
99.64M
C$ 16.440M
C$ 0.05
-0.005 -9.09
935,193
320.55M
C$ 16.030M
US$ 8.42
-0.28 -3.22
1,823
1.82M
US$ 15.320M
US$ 1.01
-0.01 -0.98
67,158
14.40M
US$ 14.540M
C$ 0.08
0.005 7.14
2,000
188.08M
C$ 14.110M
US$ 1.88
0.78 70.63
40.75M
7.44M
US$ 13.960M
US$ 2.32
0.03 1.31
962
5.81M
US$ 13.480M
US$ 2.10
0.83 65.35
26,683
6.22M
US$ 13.060M
US$ 2.10
-0.13 -5.93
7,900
5.85M
US$ 12.290M
US$ 1.91
-0.16 -7.73
19,318
6.23M
US$ 11.900M
US$ 0.82
-0.02 -2.08
24,928
14.37M
US$ 11.820M
US$ 0.40
-0.01 -2.47
19,728
29.00M
US$ 11.460M
US$ 3.08
-0.12 -3.75
902
3.51M
US$ 10.810M
US$ 0.46
-0.10 -17.86
473,879
21.89M
US$ 10.070M
C$ 0.14
-0.06 -28.21
224,500
71.31M
C$ 9.980M
US$ 3.07
-0.30 -8.90
51,302
2.90M
US$ 8.900M
US$ 0.47
-0.07 -13.00
4,830
18.63M
US$ 8.770M
US$ 0.47
0.00 0.00
0
17.39M
US$ 8.170M
US$ 0.84
-0.01 -1.58
8,702
9.43M
US$ 7.920M
US$ 3.80
0.00 0.00
0
2.01M
US$ 7.640M
US$ 5.09
-0.07 -1.36
1,208
1.47M
US$ 7.480M
US$ 2.23
-0.15 -6.29
19,633
3.23M
US$ 7.200M
C$ 0.13
0.00 0.00
0
55.00M
C$ 7.150M
US$ 0.42
-0.03 -6.44
116,971
16.82M
US$ 7.080M
US$ 0.09
0.00 0.00
0
70.46M
US$ 6.340M
US$ 0.08
0.00 0.00
0
73.90M
US$ 6.070M
US$ 1.92
0.06 2.95
25,646
3.12M
US$ 5.990M
US$ 3.51
-0.12 -3.31
5,860
1.68M
US$ 5.900M
US$ 0.43
0.03 8.17
848,510
13.08M
US$ 5.650M
US$ 0.02
0.00 0.00
0
286.49M
US$ 5.590M
US$ 1.72
0.07 4.24
3,135
3.22M
US$ 5.540M
US$ 0.86
-0.02 -1.74
52,442
6.36M
US$ 5.460M
C$ 0.02
0.00 0.00
790,512
246.29M
C$ 4.930M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
US$ 0.05
0.00 0.00
56,684
96.36M
US$ 4.820M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
US$ 0.47
-0.01 -2.73
143,850
10.22M
US$ 4.770M
US$ 0.27
-0.01 -5.23
2.19M
17.63M
US$ 4.760M
US$ 0.62
0.09 16.10
336,656
7.57M
US$ 4.660M
US$ 0.33
-0.14 -29.72
618
14.12M
US$ 4.660M
US$ 0.19
0.0046 2.44
5.72M
23.46M
US$ 4.530M
US$ 1.07
-0.06 -5.31
63,414
4.10M
US$ 4.390M
US$ 0.12
0.0012 1.02
37.09M
34.96M
US$ 4.160M
US$ 0.21
-0.01 -5.50
263,195
18.05M
US$ 3.720M
US$ 0.30
0.00 0.00
0
11.77M
US$ 3.530M
US$ 5.14
-0.02 -0.39
9,116
655,616
US$ 3.370M
US$ 0.86
-0.03 -3.37
76,692
3.81M
US$ 3.280M
US$ 1.89
-0.02 -1.08
8,011
1.70M
US$ 3.210M
US$ 2.39
-0.02 -0.83
2,062
1.34M
US$ 3.200M
US$ 0.61
0.02 3.51
1.39M
5.08M
US$ 3.100M
US$ 0.97
0.0074 0.77
21,834
2.96M
US$ 2.870M
US$ 0.02
0.00 0.00
0
161.02M
US$ 2.580M
US$ 0.25
0.00 0.00
0
10.22M
US$ 2.560M
US$ 0.31
0.00 0.00
0
7.95M
US$ 2.470M
US$ 0.40
0.01 2.62
75,018
6.18M
US$ 2.470M
US$ 0.12
0.0031 2.62
9.97M
17.14M
US$ 2.080M
US$ 0.55
-0.03 -5.00
1,743
3.73M
US$ 2.060M
US$ 0.73
-0.02 -2.14
29,575
2.78M
US$ 2.030M
US$ 0.32
-0.02 -5.71
10,127
5.31M
US$ 1.700M
US$ 1.29
0.01 0.78
28,109
1.10M
US$ 1.420M
US$ 0.05
0.00 0.00
0
28.90M
US$ 1.300M
US$ 0.04
-0.05 -53.22
1,420
29.72M
US$ 1.250M
US$ 0.13
0.00 0.00
0
5.24M
US$ 665K
C$ 0.01
0.00 0.00
0
48.23M
C$ 482K
US$ 0.0006
0.00 0.00
0
507.29M
US$ 304K
US$ 0.04
-0.14 -78.67
18,300
5.77M
US$ 213K
US$ 4.10
0.00 0.00
15,358
-
US$ -
US$ 5.96
-0.13 -2.13
2,675
-
US$ -
C$ 1.43
0.00 0.00
3,800
-
C$ -
US$ 28.36
0.00 0.00
494,854
-
US$ -

Latest News From Medical Stocks


Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual...

91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved 100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed 89% of Venous Ulcers with a Duration of More Than One Year Prior to VenoValve Surgery Have Fully Healed or Improved No Ulcer Recurrences Company on Track to File Application Seeking VenoValve FDA Approval in Q4 2024 IRVINE, CA / ACCESSWIRE / June 21,... Read more


Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27

CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who... Read more


Therma Bright Closes Second & Final Tranche of Fully Subscribed Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the second and final tranche ("Final Tranche") of its previously announced $1,000,0000 non-brokered private placement (the "Offering"). Under the Final Tranche, Therma issued 14,550,000... Read more


Radiopharm Receives Strategic Investment for up to A$18 million

Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024 Option for Lantheus to invest a further A$7.5m within 6 months on the same terms Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement SYDNEY, June 20, 2024... Read more


NeuroOne Medical Technologies Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation

ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024 Specific procedure code positions OneRF™ Ablation System for broader adoption and awareness throughout the healthcare system EDEN PRAIRIE, Minn., June 20, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and... Read more


Applied DNA Sciences and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ:MRVI)... Read more



Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products. The four products – FemaSeed®, FemVue®, FemCerv®, and FemCath®... Read more


Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.  The newly issued patent entitled, “T... Read more


Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances Multiple Robotic Systems Already Received by the Site to Allow Inventory Readiness in Support of Trial BRAINTREE, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced its agreement with Brigham and Women’s Hospital (BWH), a leading academic medical center located in Boston, Massachusetts,... Read more


Allurion Technologies Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

Patients gained an average of 5.6% in lean body mass during the Allurion Program Separate studies of patients on GLP-1 therapy report an average lean mass loss of 11%1 NATICK, Mass. / Jun 20, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program.... Read more


First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion

Reminder: Management “CEO Chat” with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time BURLINGTON, Mass. / Jun 20, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft... Read more


Critical Path and Centogene MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development for lysosomal diseases (LDs) and... Read more


Numinus Wellness Announces Strategic Acquisition of MedBright AI

Plans name change to "Numinus Intelligence" leveraging its current revenue-generating operations to AI-enable mental health clinics across the U.S. The strategic combination merges MedBright's AI-enabled clinical solution capabilities with Numinus' deep data and vast experience with drug-assisted mental health treatment to improve clinical operations and capitalize on reimbursable offerings Leaders from MedBright AI team with extensive experience in U.S. healthcare... Read more


Theralase Technologies: Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy

TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead drug formulation, Rutherrin® was... Read more


Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible with both Dexcom G6 and Abbott... Read more


Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes

Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. ADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s.1,2 New Dexcom G7 automated insulin delivery integrations* further solidify the company’s undisputed leadership in CGM connectivity. Recently released Dexcom G7 app updates, including Direct to Apple Watch,†... Read more


Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates

Omnipod 5, the world’s first tubeless automated insulin delivery (AID) system integrated with Dexcom G6, is now available in France Full commercial launch of Omnipod 5 with Dexcom G7 integration has commenced in the U.S. Omnipod 5 App for iPhone begins limited market release in the U.S. ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod®... Read more


Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

SAN DIEGO / Jun 20, 2024 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude “JC” Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. “JC brings deep experience... Read more


Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics

WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.   Ms. Sawyer... Read more


Theralase Technologies: Rutherrin Demonstrates Complete Response in Lung Cancer Preclinically

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation, Rutherrin®, has demonstrated an ability... Read more


Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device. The VASCADE MVP XL system expands Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen... Read more


Milestone Scientific Receives Regulatory Approval to Market CompuFlo® Epidural System in Brazil

Brazil is the 9th largest economy in the world with more than 21 million people suffering from chronic back pain An estimated 4-5 million epidural anesthesia procedures are performed annually in Brazil; potential to expand this addressable market due to CompuFlo’s technological advantages ROSELAND, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless... Read more


Theralase Technologies: Rutherrin Increases Efficacy of Immunotherapy Preclinically

TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead drug formulation, Rutherrin®, has... Read more


Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP

Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the College of American Pathologists (CAP) has recently accepted Telo Genomics' submission to add Telo's test for smoldering multiple myeloma (SMM), T... Read more


Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is entering the next phase of its planned 510(k) submission to the FDA. The Company has successfully completed subject screening for its Pharmacokinetic (PK) Study and will begin dosing and sampling study subjects today. INBS’ PK study is... Read more


Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical Granted Full Ethics Approval From the Human Research Ethics Committee at Central Adelaide Local Health Network for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, June 18, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases,... Read more


Boston Scientific Announces Agreement to Acquire Silk Road Medical

Acquisition adds innovative technology for stroke prevention to vascular portfolio MARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called... Read more


Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions

SAN DIEGO / Jun 18, 2024 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Product Theater The Company will host a Product Theater on Saturday, June 22 from 10:15 am - 11:00 am EDT at Product Theater #1. Meet Tandem Mobi: Tiny pump,... Read more


Tivic Health: Christina Valauri Appointed to Board of Directors

Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health’s Governance Team SAN FRANCISCO / Jun 18, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024. Ms. Valauri has served as a strategic advisor to the company... Read more


Prenetics Global Announces First Quarter 2024 Financial Results

First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range of US$33 million to US$36 million LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the first quarter ended March... Read more


iRhythm Technologies Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding... Read more


New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June 18-22, 2024 in Chicago, IL. The presentation, entitled "The Impact of VenoValve... Read more


Inspira Technologies Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

RA'ANANA, Israel, June 17, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce today that the Company will present at the annual iECOs Conference in Herzliya, Israel on June 18th, 2024. The Company will present the INSPIRA™ ART100 System, recently 510(k) U.S. Food and Drug Administration-cleared, and which is pending... Read more


Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for indications beyond CIEDs, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting... Read more


Charles River Laboratories and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy

Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial WILMINGTON, Mass. / Jun 17, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access... Read more


Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research... Read more


Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejection AUSTIN, Texas / Jun 17, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients. Traditionally, donor-derived... Read more


Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress

Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care VAUGHAN, Ontario / Jun 17, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take... Read more


Helius Medical Technologies Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke

Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrational program in stroke  In Canada, an additional study on the use of Portable Neuromodulation Stimulator (PoNS®) Therapy to treat stroke has started to support Canadian reimbursement and U.S. approval for stroke  NEWTOWN, Pa., June 17, 2024 (GLOBE NEWSWIRE) --... Read more


Avinger Announces Closing of up to $24 Million Public Offering

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants REDWOOD CITY, CA / ACCESSWIRE / June 17, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the closing its previously announced... Read more


Elutia Announces $13.26 Million Registered Direct Offering

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per prefunded warrant in... Read more


Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso’s Board SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. “We are pleased to strengthen our... Read more


Co-Diagnostics Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY, June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first... Read more


Join Sharps Technology’s Exclusive Live Investor Webinar and Q&A Session on June 18

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Robert Hayes, CEO of Sharps Technology, who will share insight into the Company’s recent Asset Purchase... Read more


Senseonics to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions

GERMANTOWN, Md. / Jun 13, 2024 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL. Breakfast and refreshments will be provided beginning at... Read more


Qiagen’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs

Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels and higher test volumes. The latest... Read more


Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices. Mark White, CEO of Nexalin Technology, stated, "We are pleased to announce... Read more


Applied DNA Sciences Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health ("NYSDOH") approved the Company's TR8™ PGx ("TR8") pharmacogenomic (PGx) testing service. The Company is currently in discussions to provide large-scale testing to enterprise customers, healthcare networks, and concierge physicians seeking to add PGx... Read more


Movano Health Applies Advanced AI through Deep Learning to Deliver Improved Accuracy of Heart Rate in Motion

Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif., June 13, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing. The Company recently released an engineering accuracy study directed by Movano Health Founder and CTO Michael Leabman, Enhanced... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB